Cat Allergy - Pipeline Review, H1 2015

Published: Feb, 2015 | Pages: 49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cat Allergy - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Cat Allergy - Pipeline Review, H1 2015', provides an overview of the Cat Allergy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cat Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cat Allergy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cat Allergy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Cat Allergy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Cat Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cat Allergy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cat Allergy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cat Allergy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cat Allergy Overview 6
Therapeutics Development 7
Pipeline Products for Cat Allergy - Overview 7
Pipeline Products for Cat Allergy - Comparative Analysis 8
Cat Allergy - Therapeutics under Development by Companies 9
Cat Allergy - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Cat Allergy - Products under Development by Companies 13
Cat Allergy - Companies Involved in Therapeutics Development 14
ALK-Abello A/S 14
Amgen Inc. 15
Biomay AG 16
Circassia Pharmaceuticals plc 17
Laboratorios LETI S.L. 18
Cat Allergy - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
ALK Recombinant Cat Vaccine - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Allergen for Cat Allergy - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AMG-157 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
BM-36 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Cat Epithelial Allergenic Extract - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cat-SPIRE - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Cat Allergy - Recent Pipeline Updates 37
Cat Allergy - Dormant Projects 40
Cat Allergy - Discontinued Products 41
Cat Allergy - Product Development Milestones 42
Featured News & Press Releases 42
Jan 08, 2015: Circassia Completes Recruitment for Cat Allergy Treatment Pivotal Phase III Study 42
Feb 25, 2013: Circassia's ToleroMune Cat Allergy Treatment Maintains Symptom Improvement Two Years After Start Of Short-course Therapy 42
Oct 04, 2012: Circassia Initiates Pivotal Phase III ToleroMune Trial In Cat Allergen-induced Rhinoconjunctivitis 43
Sep 27, 2012: Circassia Announces Publication Of ToleroMune Cat Allergy Treatment Clinical Results In Journal of Allergy And Clinical Immunology 44
Jun 13, 2011: Circassia's Rapid Four-Dose ToleroMune Treatment Maintains Significant Reduction In Allergy Symptoms During 12-Month Follow-up 44
Feb 01, 2011: Circassia's ToleroMune T-cell Vaccine Achieves Significant Reduction In Allergy Symptoms In Key Phase II Clinical Study 45
Sep 30, 2010: Circassia Initiates Phase II Trials Of Novel Grass And Ragweed Allergy Therapies And Advances Phase III Plans For Cat Allergy T-cell Vaccine 46
Jan 19, 2010: Circassia Extends Its Clinical-Stage Portfolio With Phase II Trials of T-cell Vaccines Against House Dust Mite And Cat Allergies 46
Nov 20, 2009: Circassia Announces Successful Results From Phase II Clinical Study Of ToleroMune Cat Allergy Therapy 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables
Number of Products under Development for Cat Allergy, H1 2015 7
Number of Products under Development for Cat Allergy - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Cat Allergy - Pipeline by ALK-Abello A/S, H1 2015 14
Cat Allergy - Pipeline by Amgen Inc., H1 2015 15
Cat Allergy - Pipeline by Biomay AG, H1 2015 16
Cat Allergy - Pipeline by Circassia Pharmaceuticals plc, H1 2015 17
Cat Allergy - Pipeline by Laboratorios LETI S.L., H1 2015 18
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Stage and Target, H1 2015 21
Number of Products by Stage and Mechanism of Action, H1 2015 22
Number of Products by Stage and Route of Administration, H1 2015 24
Number of Products by Stage and Molecule Type, H1 2015 26
Cat Allergy Therapeutics - Recent Pipeline Updates, H1 2015 37
Cat Allergy - Dormant Projects, H1 2015 40
Cat Allergy - Discontinued Products, H1 2015 41